Kristina S Boye - JoVE Visualize

Showing results (121-130 of 130) with videos related to

Pageof 13

Sort By:

You have reached the last page of results.This site can display upto 130 results.

Diabetes, Obesity & Metabolism|February 5, 2019

Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United StatesKristina S Boye, Matthew C Riddle, Hertzel C Gerstein, et al.

Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 7, 2021

The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline CharacteristicsLuis-Emilio García-Pérez, Kristina S Boye, Myriam Rosilio, et al.

Journal of Medical Economics|April 24, 2019

Patient preferences and health state utilities associated with dulaglutide and semaglutide injection devices among patients with type 2 diabetes in ItalyKristina S Boye, Louis S Matza, Katie D Stewart, et al.

Journal of Medical Economics|July 4, 2024

The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): resource use and costs of treatment in clinical practice in France, Germany, and ItalyAnnabel Barrett, Kristina S Boye, Luis-Emilio García-Pérez, et al.

Diabetes, Obesity & Metabolism|September 15, 2023

The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Final patient-reported outcomes at 24 monthsKristina S Boye, Jérémie Lebrec, Anne Dib, et al.

Value in Health Regional Issues|April 29, 2018

The Health Technology Assessment Environment in Mainland China, Japan, South Korea, and Taiwan-Implications for the Evaluation of Diabetes Mellitus TherapiesTessa Kennedy-Martin, Beth D Mitchell, Kristina S Boye, et al.

Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|November 25, 2019

Patient Preferences and Health State Utilities Associated with Mealtime Insulin Concentrations Among Patients with Diabetes in ItalyLouis S Matza, Beatrice Osumili, Katie D Stewart, et al.

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 21, 2019

United States Valuation of EQ-5D-5L Health States Using an International ProtocolA Simon Pickard, Ernest H Law, Ruixuan Jiang, et al.

Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|July 18, 2021

Risk Factors Associated with COVID-19 Hospitalization and Mortality: A Large Claims-Based Analysis Among People with Type 2 Diabetes Mellitus in the United StatesKristina S Boye, Elif Tokar Erdemir, Nathan Zimmerman, et al.

Diabetes, Obesity & Metabolism|October 25, 2019

Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER)Louis S Matza, Kristina S Boye, Katie D Stewart, et al.

Pageof 13

Showing results (121-130 of 130) with videos related to

Sort By:

Pageof 13

You have reached the last page of results.This site can display upto 130 results.

Diabetes, Obesity & Metabolism|February 5, 2019

Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United StatesKristina S Boye, Matthew C Riddle, Hertzel C Gerstein, et al.

Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 7, 2021

The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline CharacteristicsLuis-Emilio García-Pérez, Kristina S Boye, Myriam Rosilio, et al.

Journal of Medical Economics|April 24, 2019

Patient preferences and health state utilities associated with dulaglutide and semaglutide injection devices among patients with type 2 diabetes in ItalyKristina S Boye, Louis S Matza, Katie D Stewart, et al.

Journal of Medical Economics|July 4, 2024

The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): resource use and costs of treatment in clinical practice in France, Germany, and ItalyAnnabel Barrett, Kristina S Boye, Luis-Emilio García-Pérez, et al.

Diabetes, Obesity & Metabolism|September 15, 2023

The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Final patient-reported outcomes at 24 monthsKristina S Boye, Jérémie Lebrec, Anne Dib, et al.

Value in Health Regional Issues|April 29, 2018

The Health Technology Assessment Environment in Mainland China, Japan, South Korea, and Taiwan-Implications for the Evaluation of Diabetes Mellitus TherapiesTessa Kennedy-Martin, Beth D Mitchell, Kristina S Boye, et al.

Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|November 25, 2019

Patient Preferences and Health State Utilities Associated with Mealtime Insulin Concentrations Among Patients with Diabetes in ItalyLouis S Matza, Beatrice Osumili, Katie D Stewart, et al.

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 21, 2019

United States Valuation of EQ-5D-5L Health States Using an International ProtocolA Simon Pickard, Ernest H Law, Ruixuan Jiang, et al.

Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|July 18, 2021

Risk Factors Associated with COVID-19 Hospitalization and Mortality: A Large Claims-Based Analysis Among People with Type 2 Diabetes Mellitus in the United StatesKristina S Boye, Elif Tokar Erdemir, Nathan Zimmerman, et al.

Diabetes, Obesity & Metabolism|October 25, 2019

Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER)Louis S Matza, Kristina S Boye, Katie D Stewart, et al.

Pageof 13